Forty patients with spontaneous bacterial peritonitis, three ofwhom had complicating acute hepatitis syndrome, eight lateonset hepatic failure, and 29 with cirrhosis, were treated with ceftriaxone 2 g intravenously once daily for 5 days. Ascitic fluid culture was positive in 28 patients, with Escherichia coli and Kiebsiella as common isolates. All the bacteria isolated were sensitive to ceftriaxone except Enterococcus faecalis, which was isolated in a cirrhotic patient. All culturepositive patients sensitive to ceftriaxone showed bacteriological cure and 26 (65%) patients showed cytological cure after 48 hours of treatment. A total of 95% were cured of their infection after 5 days of treatment. Twelve (30%) patients died during hospitalisation after documented cure of their spontaneous bacterial peritonitis (renal failure, gastrointestinal bleed and cerebral oedema were the primary causes of death). Infectionrelated mortality due to Pseudomonas septicaemia was seen in one cirrhotic patient.
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Keywords: bacterial peritonitis; ceftriaxone Spontaneous bacterial peritonitis (SBP) is a bacterial infection of ascitic fluid in the absence of either a contiguous or localised intraperitoneal source of infection and complicates virtually all forms of parenchymal liver diseases. A first-generation cephalosporin (kanamycin) and ampicillin-gentamicin combinations were initially recommended as therapy,' however, the use of aminoglycoside in days of consideration of therapy were excluded from the study. All patients with ascites underwent paracentesis on admission to hospital and repeat paracentesis was performed after 48 ± 2 hours of initiation of therapy and after completion of 5 days of therapy. Ascitic fluid was sent to the laboratory for cell count, culture sensitivity and chemical parameters. The American Optical Neubauer Hemacytometer was used for ascitic fluid cell count. The differential was performed manually after Wright staining and therefore the white cell count derived by haemacytometer was corroborated; 10 ml of ascitic fluid was inoculated into each of the two blood culture bottles at the bedside. Isolation and identification of positive culture was performed by Ceftriaxone (Monoceff, Aristo), 2 g intravenously over 15 minutes, was given once daily for 5 days. The drug therapy was considered to be effective when the ascitic fluid PMN count showed a fall of more than 50%; patients were considered cured when there was no clinical evidence of infection, sterile ascitic fluid, and an ascitic fluid PMN count <250 cells/mm3." All the patients who were cured of their infection received prophylactic norfloxacin 400 mg once daily.
Statistical analysis was performed on ascitic PMN count using students t-test and chi-square test was used to analyse culture positivity.
Results
Forty patients with SBP were included in the study, 24 men and 16 women; they had underlying acute hepatitis (three patients), late-onset hepatic failure (eight), and cirrhosis (29). Among cirrhotics, 83% of patients were of Child Pugh class C. The mean age of presentation was 49.7 ± 12.5 years (table 1) .
Prothrombin activity was reduced in most patients, and liver function tests were consistent with underlying liver disease. Bilirubin and alanine transaminase were raised considerably in the patients with acute hepatitis and late-onset hepatic failure, with mild elevation in cirrhotics. Total serum protein and albumin were reduced in all three groups with lower values in cirrhotics. Kidney function tests were deranged in 15 patients on admission; this was greater efficacy and safety in treatment of severe infections in cirrhotics and listed it as the treatment of choice. Gomez Jimenez et al7 compared cefonicid (2 g every 12 h) and ceftriaxone (2 g every 24 h) and found ceftriaxonesusceptible strains in 94% patients and cefonicid-susceptible in 91.5% patients. All the patients treated with ceftriaxone and 94% of those treated with cefonicid were cured of their infections.
Ceftriaxone has an excellent spectrum of activity against Gram-negative organisms and good activity against Gram-positive organisms, including Streptococcus pneumoniae.' Almost all organisms isolated from SBP patients were sensitive to ceftriaxone except Bacteroidesfragilis and Efaecalis, which are rarely predisposing organisms.! Ceftriaxone has an unique half-life of 8 hours and can be given once daily.8 The antibiotic concentration in ascitic fluid:MIC ratio for ceftriaxone (2 g) was greater than 100 throughout the dose interval (24 h) against organisms isolated from SBP patients.! Runyon et al" reported that short-course (5-day) treatment of SBP is as efficacious as long-course (10-day) therapy. It is because of these characteristics that ceftriaxone 2 g once daily for 5 days was used in this study.
In 1982, Thomas and Fromkes" reported two patients with acute hepatitis B who developed SBP. In a series of 82 patients with acute hepatitis decompensated with ascites, 26 (32%) had SBP."4 Bacteraemia and/or SBP were reported in 12 out of 47 patients with late onset hepatic failure,9 while SBP was found in 38% of a series of 148 cases of subacute hepatic failure,"5 and up to 15% of 224 patients with chronic liver disease. '6 Bedside inoculation of ascitic fluid in blood culture bottles has yielded better results than delayed inoculation in the laboratory. In our study, ascitic fluid culture positivity was seen in 28 (70%) patients, of whom 96% were sensitive to ceftriaxone. Toledo et al'7 found culture positivity in 57% of SBP patients most of which were Gram negative. Gomez Jimenez et ar in 1993 found culture positivity in 78% of 60 patients with SBP, of whom 94% were susceptible to ceftriaxone.
Ascitic fluid opsonic activity is an important protective mechanism against SBP. A prospective study demonstrated that patients with low concentrations of protein in ascitic fluid were susceptible to SBP.'8 Ascitic fluid protein was found to be less than 1 g/dl in 88.5% patients with acute hepatitis. 14 Our study confirmed these results, although there was no statistically significant difference in culture positivity in patients with ascitic fluid albumin >1 g/dl.
In our study, the 48-hour treatment with ceftriaxone showed cytological evidence of cure in 65% ofpatients and 100% bacteriological cure in ceftriaxone-susceptible strains. A total of 95% patients were cured of their infection after receiving ceftriaxone for 5 days. Our results were consistent with those of Gomez Jimenez,7 who recorded a cytological cure in 59% of patients and 100% bacteriological cure after 72 hours of treatment. Out of 40 patients, 27 (67.5%) left the hospital alive and 13 (32.5%) died during hospitalisation due to underlying liver disease. On admission 15 patients had deranged kidney function tests (creatinine >2 mg/dl); in nine of these kidney functions improved while in the other six there was progressive deterioration in renal function, leading to death. Four patients died of major variceal bleed and cerebral oedema was the cause of death in two patients on ventilatory support; one patient died of Pseudomonas septicaemia.
In our study there was no statistically significant difference in culture positivity among survivors and non-survivors. Runyon et al '9 reported a 50% mortality of culture-negative neutrocytic ascites, which was not statistically different from that of culture-positive ascites (70%). Other studies have reported an 85% cure rate with cefotaxime,6 and amoxycillinclavulanic acid.4 In contrast, our study with ceftriaxone 2 g once daily for 5 days showed a 95% cure rate; our results are supported by those of Gomez Jimenez, who achieved 100% cure rate in SBP. The duration of therapy with ceftriaxone is much shorter, and the hospital stay of patients is markedly reduced, which adds to the cost effectiveness of this regimen. Therefore ceftriaxone may be regarded as empiric treatment of choice in patients of SBP with underlying parenchymal liver disease.
